RecruitingNCT07268066

Implementation of the Methylome in the Characterization of Solid Tumors


Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

180 participants

Start Date

May 21, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to investigate the functional consequences of specific methylation changes and to examine the clinical implications of these alterations. Methylation analysis is a powerful tool for understanding the molecular mechanisms of brain tumors and other solid tumors and can help identify new diagnostic and therapeutic targets. By analyzing DNA methylation patterns in tumor tissue, it is possible to identify genes that are silenced or activated by methylation. This information can be used to develop new biomarkers for early diagnosis and to identify new therapeutic targets that can be used to reverse methylation-mediated gene silencing.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Confirmed diagnosis of one of the following types of cancer: gliomas, malignant thyroid neoplasms, or endometrial carcinomas (according to the WHO Nomenclature)
  • Availability of adequate material for analysis at the laboratory, specifically availability of at least 3 sections of 10 µm of FFPE

Exclusion Criteria1

  • no

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

IRCCS Azienda Ospedaliero Univesitaria di Bologna

Bologna, BO, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07268066


Related Trials